Download Mobile App

Video Library

Partner Sites

MedImaging

PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack

3D Scanning Approach Enables Ultra-Precise Brain Surgery

X-Ray Breakthrough Captures Three Image-Contrast Types in Single Shot

Novel Imaging Approach to Improve Treatment for Spinal Cord Injuries

Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers

Featured Links

Medical Equipment Marketplace
Visit our all new website Trademed.com where buyers and sellers can find the best medical device and equipment.

New COVID-19 Rapid Antigen Test Can Be Run on Mobile Testing Platform for Lab-Quality Test Results in 15 Minutes

By HospiMedica International staff writers
Posted on 08 Jan 2021

A new COVID-19 rapid antigen test that provides lab-quality test results in 15 minutes could offer a frequent, fast, cheap and easy COVID-19 screening solution to help meet the surging demand for tests and relieve the global supply chain.

Nanōmix, Inc.’s (Emeryville, CA, USA) eLab COVID-19 Rapid Antigen test is a low-cost, easy-to-use, point-of-care test that provides results in 15 minutes with lab-quality accuracy. More...

The battery-powered, handheld device utilizes proprietary biosensor and microfluidics technologies to perform an electrochemical detection in a single-use, disposable cartridge. The Nanomix eLab is a mobile platform that can test multiple biomarkers using multiple detection methods from a single patient sample in laboratory or non-laboratory environments - so any location, including rural or remote, can have rapid, lab-quality tests for COVID-19 and a variety of other diseases and conditions. The Nanomix eLab is battery powered, portable, and easy-to-use by non-professionals in a variety of critical applications such as assisted living communities, skilled nursing facilities, emergency medical services, schools, businesses, and remote towns and villages.

The company’s eLab COVID-19 assay has also been selected as a finalist in the XPRIZE Rapid COVID Testing competition. The USD 5 million, six-month competition aims to increase COVID-19 testing capabilities 100-times past the current standard, the level of increase needed to more safely return to everyday activities.

“We are excited to be selected as a finalist in the XPRIZE Rapid COVID Testing,” said David Ludvigson, CEO of Nanomix. “The goals of the competition – to develop frequent, fast, low-cost, and easy-to-use COVID tests – align with our corporate mission. The eLab Rapid COVID Antigen test, together with our eLab Rapid COVID Antibody test, form a complete offering for COVID-19 testing.”

“Fast, affordable, and accessible testing is crucial to containing the COVID-19 pandemic and safely reopening schools, businesses and other vital institutions around the world,” said Anousheh Ansari, CEO of XPRIZE. “XPRIZE Rapid COVID Testing competition is inspiring the best entrepreneurs and scientists to form teams and come together to work towards rapid, affordable COVID-19 testing at scale, and ultimately, getting the world up and running again.”

Related Links:
Nanōmix, Inc.

Visit expo >

Gold Member

12-Channel ECG

CM1200B

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

Radiation Safety Barrier

RayShield Intensi-Barrier

Digital Color Doppler Ultrasound System

MS22Plus

Read the full article by registering today, it's FREE!

Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!